FDA approves Blenrep for relapsed or refractory multiple myeloma

Published Date: 31 Oct 2025

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

2.

Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.

3.

The Effect of Common Steroids on Cancer Treatments.

4.

De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer

5.

Oleanolic acid from grapes may increase chemotherapy effectiveness


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot